Univariate and multivariate model of OS
| . | Univariate . | Multivariate . | ||||||
|---|---|---|---|---|---|---|---|---|
| n . | HR . | 95% CI . | P . | n . | HR . | 95% CI . | P . | |
| PTCL-GATA3 vs PTCL-TBX21 by IHC | 128 | 2.39 | 1.55-3.70 | <.0001 | 67 | 2.75 | 1.51-5.01 | .0009 |
| Sex: male vs female | 128 | 1.09 | 0.71-1.69 | .69 | ||||
| Morphology | ||||||||
| Monomorphous vs polymorphous | 121 | 1.77 | 1.14-2.75 | .0095 | ||||
| CD8+ vs CD8− | 120 | 0.75 | 0.46-1.22 | .24 | ||||
| CD4+ vs CD4− | 121 | 1.24 | 0.76-2.05 | .39 | ||||
| CTX phenotype vs non-CTX phenotype | 70 | 0.87 | 0.46-1.63 | .65 | ||||
| IPI factors | ||||||||
| High IPI vs low IPI | 74 | 2.13 | 1.21-3.74 | .0089 | 67 | 1.8 | 1.0-3.24 | .05 |
| Age: >60 y vs ≤60 y | 124 | 1.95 | 1.27-3.01 | .0025 | ||||
| Stage: III/IV vs I/II | 85 | 1.77 | 0.91-3.44 | .092 | ||||
| High LDH vs normal LDH | 78 | 1.69 | 0.95-3.02 | .074 | ||||
| Extranodal sites: >1 vs ≤1 | 77 | 1.85 | 1.04-3.29 | .035 | ||||
| . | Univariate . | Multivariate . | ||||||
|---|---|---|---|---|---|---|---|---|
| n . | HR . | 95% CI . | P . | n . | HR . | 95% CI . | P . | |
| PTCL-GATA3 vs PTCL-TBX21 by IHC | 128 | 2.39 | 1.55-3.70 | <.0001 | 67 | 2.75 | 1.51-5.01 | .0009 |
| Sex: male vs female | 128 | 1.09 | 0.71-1.69 | .69 | ||||
| Morphology | ||||||||
| Monomorphous vs polymorphous | 121 | 1.77 | 1.14-2.75 | .0095 | ||||
| CD8+ vs CD8− | 120 | 0.75 | 0.46-1.22 | .24 | ||||
| CD4+ vs CD4− | 121 | 1.24 | 0.76-2.05 | .39 | ||||
| CTX phenotype vs non-CTX phenotype | 70 | 0.87 | 0.46-1.63 | .65 | ||||
| IPI factors | ||||||||
| High IPI vs low IPI | 74 | 2.13 | 1.21-3.74 | .0089 | 67 | 1.8 | 1.0-3.24 | .05 |
| Age: >60 y vs ≤60 y | 124 | 1.95 | 1.27-3.01 | .0025 | ||||
| Stage: III/IV vs I/II | 85 | 1.77 | 0.91-3.44 | .092 | ||||
| High LDH vs normal LDH | 78 | 1.69 | 0.95-3.02 | .074 | ||||
| Extranodal sites: >1 vs ≤1 | 77 | 1.85 | 1.04-3.29 | .035 | ||||
CTX, cytotoxic. See Table 1 for expansion of other abbreviations.